The rate of decrease in coronary heart disease (CHD) mortality in the United States has slowed, probably in association with the aging of the population and the increasing rates of obesity, metabolic syndrome, and diabetes. Worldwide, guidelines for reducing risk of CHD and lowering lipid levels must continue to evolve to reflect disease and risk factor trends that reflect improvements in the knowledge of individual risk factors and the effects of clustered risk factors in specific patients. According to current guidelines used in the United States, Europe, and Canada for risk assessment and risk reduction, the trend is moving away from simple measurement of cholesterol and toward a more global risk assessment. An increasing number of factors are included in risk assessment, and the recommended intensity of intervention with lipid-lowering treatment continues to increase among patients considered to be at high risk.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.3810/pgm.09.2004.suppl34.206 | DOI Listing |
Curr Drug Saf
January 2025
Department of Chemistry, K J Somaiya College of Science and Commerce, Vidyavihar, Mumbai-77, India.
The presence of N-nitrosamine impurities in pharmaceutical products is well known. In 2019, it resulted in drug recall by the Food and Drug Administration (FDA). Soon, several groups identified the presence of many N-nitrosamines (NAs) in various Active Pharmaceutical Ingredients (APIs) and drug formulations worldwide.
View Article and Find Full Text PDFEpilepsia Open
January 2025
Division of Pediatric Critical Care Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Objectives: Pediatric status epilepticus (SE) carries a high risk of morbidity and mortality and can result in neurologic injury. Establishing seizure activity on conventional EEG (cEEG) is essential but can delay treatment of seizures due to technician limitations. Rapid response EEG (rrEEG) device Ceribell and its Brain Stethoscope function can be used and interpreted rapidly by bedside providers with minimal training.
View Article and Find Full Text PDFInt J Toxicol
January 2025
Chemical and Preclinical Safety Department, Global Chemical and Preclinical Safety, Merck KGaA, Darmstadt, Germany.
The therapeutic window of antibody drug-conjugates (ADC) remains challenging due to safety issues such as interstitial lung disease (ILD) observed with specific deruxtecan-based ADCs. To avoid ILD, we designed M9140 by conjugating the maleimide-containing hydrophilic β-glucuronide linker to exatecan and our anti-CEACAM5 (CarcinoEmbryonic Antigen-related Cell Adhesion Molecule 5) specific antibody. Following repeated iv-infusion at 3 to 30 mg/kg of M9140 every 3 weeks, the pathological findings obtained in cynomolgus monkeys were confined to gastrointestinal and hematolymphoid tissues and resembled the toxicity of exatecan.
View Article and Find Full Text PDFIndian Pediatr
January 2025
Department of Neonatology, St John's Medical College Hospital, Bangalore, Karnataka, India.
Introduction: Neonatal intensive care unit (NICU) graduates are at risk of sudden death at home after discharge. Many of these deaths can be prevented if parents can identify warning signs and provide immediate resuscitation.
Objectives: The primary objective of this study was to assess the feasibility of training parents of high-risk neonates in low- and middle-income countries (LMICs) to deliver infant resuscitation effectively.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!